Capricor stock on watch after key EU designations
CAPR Stock | USD 18.62 0.83 4.67% |
Slightly above 54% of Capricor Therapeutics' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Capricor Therapeutics suggests that some traders are interested. Capricor Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Capricor Therapeutics. Many technical investors use Capricor Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Capricor |
Capricor Therapeutics stock in focus as company receives Orphan Drug and ATMP designations from the EU regulator for its lead drug deramiocel. Read more here.
Read at seekingalpha.com
Capricor Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Capricor Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Capricor Therapeutics Fundamental Analysis
We analyze Capricor Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Capricor Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Capricor Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Capricor Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Capricor Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Capricor Therapeutics stock to make a market-neutral strategy. Peer analysis of Capricor Therapeutics could also be used in its relative valuation, which is a method of valuing Capricor Therapeutics by comparing valuation metrics with similar companies.
Peers
Capricor Therapeutics Related Equities
CDTX | Cidara Therapeutics | 16.91 | ||||
SLNO | Soleno Therapeutics | 5.77 | ||||
ANAB | AnaptysBio | 5.20 | ||||
AKTX | Akari Therapeutics | 4.84 | ||||
UNCY | Unicycive Therapeutics | 3.92 | ||||
KROS | Keros Therapeutics | 3.86 | ||||
BPTH | Bio Path | 2.50 | ||||
IDYA | Ideaya Biosciences | 0.71 | ||||
MGTX | MeiraGTx Holdings | 0.17 | ||||
PULM | Pulmatrix | 0.16 | ||||
PHIO | Phio Pharmaceuticals | 2.37 | ||||
MBRX | Moleculin Biotech | 3.53 | ||||
NXTC | NextCure | 7.75 |
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.